Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NinePoint Medical Looks Deep For Barrett’s Esophagus

Executive Summary

NinePoint Medical Inc. is looking to shed some insights on the mysteries of the esophagus. The venture-backed start-up launched NvisionVLE, an imaging system that can produce real-time images of the esophagus, enabling gastroenterologists to see where they need to cut when performing biopsies of tests of worrisome esophageal tissue including Barrett’s esophagus.

You may also be interested in...



Device/Diagnostics Quarterly Deal Statistics, Q1 2014

Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.

Singapore Researchers Say Confocal Raman Spectroscopy Allows Real-Time Cancer Decisions

Researchers at the National University of Singapore said in vivo studies using Confocal Raman spectroscopy demonstrate that diagnosis of cancer in sensitive tissues can be carried out in real time. The technology, still in development phase, could diminish the need for biopsies and allow doctors to make decisions about removal on the spot.

Buyer Appetite Might Appeal To GI Device Investors

A long-time darling of venture capital, the gastrointestinal sector has yet to meet expectation of VCs who wagered on technologies to treat gastroesophageal reflux disease, Barrett’s esophagus and even obesity. But some notable acquisitions, including Covidien’s purchase of privately held Barrx, may present a ray of hope for investors in GI companies.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel